HRP20120167T1 - Heteroarilom supstituirani amidi koji sadrže zasićenu spojnicu i njihova upotreba kao farmaceutska sredstva - Google Patents

Heteroarilom supstituirani amidi koji sadrže zasićenu spojnicu i njihova upotreba kao farmaceutska sredstva Download PDF

Info

Publication number
HRP20120167T1
HRP20120167T1 HR20120167T HRP20120167T HRP20120167T1 HR P20120167 T1 HRP20120167 T1 HR P20120167T1 HR 20120167 T HR20120167 T HR 20120167T HR P20120167 T HRP20120167 T HR P20120167T HR P20120167 T1 HRP20120167 T1 HR P20120167T1
Authority
HR
Croatia
Prior art keywords
alkyl
pyridin
substituted
alkyloxy
dione
Prior art date
Application number
HR20120167T
Other languages
English (en)
Croatian (hr)
Inventor
Strobel Hartmut
Wohlfart Paulus
Zoller Gerhard
William Will David
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20120167T1 publication Critical patent/HRP20120167T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
HR20120167T 2005-06-28 2012-02-20 Heteroarilom supstituirani amidi koji sadrže zasićenu spojnicu i njihova upotreba kao farmaceutska sredstva HRP20120167T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05013870A EP1741709A1 (de) 2005-06-28 2005-06-28 Heteroaryl substituierte Amide mit gesättigtem Linker, und deren Verwendung als Pharmaka
PCT/EP2006/005706 WO2007000246A1 (en) 2005-06-28 2006-06-14 Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
HRP20120167T1 true HRP20120167T1 (hr) 2012-03-31

Family

ID=35478793

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120167T HRP20120167T1 (hr) 2005-06-28 2012-02-20 Heteroarilom supstituirani amidi koji sadrže zasićenu spojnicu i njihova upotreba kao farmaceutska sredstva

Country Status (33)

Country Link
US (1) US8518976B2 (de)
EP (2) EP1741709A1 (de)
JP (1) JP5149794B2 (de)
KR (1) KR20080027801A (de)
CN (1) CN101208328B (de)
AR (1) AR054800A1 (de)
AT (1) ATE539072T1 (de)
AU (1) AU2006264049B2 (de)
BR (1) BRPI0613717A2 (de)
CA (1) CA2611953A1 (de)
CY (1) CY1112869T1 (de)
DK (1) DK1899321T3 (de)
DO (1) DOP2006000146A (de)
ES (1) ES2378894T3 (de)
GT (1) GT200600274A (de)
HK (1) HK1122551A1 (de)
HR (1) HRP20120167T1 (de)
IL (1) IL188382A0 (de)
MA (1) MA29552B1 (de)
MX (1) MX2008000044A (de)
NO (1) NO20080523L (de)
NZ (1) NZ565041A (de)
PA (1) PA8683901A1 (de)
PE (1) PE20070102A1 (de)
PL (1) PL1899321T3 (de)
PT (1) PT1899321E (de)
RS (1) RS52266B (de)
RU (1) RU2412181C2 (de)
SI (1) SI1899321T1 (de)
TW (1) TWI378095B (de)
UY (1) UY29640A1 (de)
WO (1) WO2007000246A1 (de)
ZA (1) ZA200710002B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1939181A1 (de) * 2006-12-27 2008-07-02 sanofi-aventis Heteroaryl-substituierte Carboxamide und deren Verwendung für die Stimulierung der NO Synthase Expression
EP2310372B1 (de) 2008-07-09 2012-05-23 Sanofi Heterocyclische Verbindungen, Verfahren zu ihrer Herstellung, Arzneimitteln mit diesen Verbindungen und ihre Verwendung
US8815772B2 (en) 2012-06-29 2014-08-26 E I Du Pont De Nemours And Company Fungicidal heterocyclic carboxamides
MX2015014336A (es) 2013-04-12 2016-06-07 Obschestvo S Ogranichennoi Otveststvennostiyu Pharmentpr Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4429656Y1 (de) 1967-03-16 1969-12-08
GB1188416A (en) * 1968-04-01 1970-04-15 Ici Ltd Heterocyclic Amines
GB1231829A (de) * 1968-09-19 1971-05-12
GB1341375A (en) * 1969-11-19 1973-12-19 Smith Kline French Lab Aminoalkylimidazoles and process for their production
FR2510997A1 (fr) * 1981-08-10 1983-02-11 Sanofi Sa Nouveaux derives de la methyl-4 phenyl-6 pyridazine, procede pour leur preparation et medicaments actifs sur le systeme nerveux central en contenant
US4565814A (en) 1983-01-28 1986-01-21 Sanofi Pyridazine derivatives having a psychotropic action and compositions
ATE77817T1 (de) 1985-04-30 1992-07-15 Dresden Arzneimittel 3-cyan-pyridine, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung.
US4710502A (en) 1985-11-04 1987-12-01 American Cyanamid Company 3-heteroarylalkyl-4-quinazolinones
US4701502A (en) * 1985-12-13 1987-10-20 E. I. Du Pont De Nemours And Company Chip resistant primer composition V'
NL8800998A (nl) * 1988-04-18 1989-11-16 Cedona Pharm Bv Werkwijze voor het bereiden van een al of niet gesubstitueerd 4(5)-(omega-aminoalkyl) imidazool.
TW224974B (de) * 1991-07-02 1994-06-11 Hoffmann La Roche
GB9127304D0 (en) * 1991-12-23 1992-02-19 Boots Co Plc Therapeutic agents
AU4515696A (en) * 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
JP4272261B2 (ja) 1996-12-10 2009-06-03 アボツト・ラボラトリーズ ３−ピリジルエナンチオマーおよび鎮痛薬としてのその使用
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
WO2000003746A2 (en) 1998-07-14 2000-01-27 The Brigham And Women's Hospital, Inc. Upregulation of type iii endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
SE9803518D0 (sv) * 1998-10-15 1998-10-15 Astra Pharma Prod Novel compounds
US6489308B1 (en) * 1999-03-05 2002-12-03 Trustees Of University Of Technology Corporation Inhibitors of serine protease activity, methods and compositions for treatment of nitric-oxide-induced clinical conditions
DE19947154A1 (de) 1999-10-01 2001-10-04 Bayer Ag Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung
JP2002255971A (ja) * 2000-03-31 2002-09-11 Takeda Chem Ind Ltd 縮合複素環誘導体、その製造法および用途
US20030158245A1 (en) 2000-03-31 2003-08-21 Tsuneo Yasuma Fused heterocyclic derivatives, their production and use
CA2415899A1 (en) * 2000-07-18 2003-01-13 Chikashi Saitoh Medicine comprising dicyanopyridine derivative
TWI241190B (en) 2001-02-13 2005-10-11 Aventis Pharma Gmbh 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical
PE20020856A1 (es) 2001-02-13 2002-11-11 Aventis Pharma Gmbh 1,2,3,4-tetrahidronaftil aminas aciladas
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
MY136316A (en) 2001-02-13 2008-09-30 Sanofi Aventis Deutschland Acylated 6,7,8,9-tetrahydro-5h-benzocycloheptenyl amines and their use as pharmaceutical.
DE10110747A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung
WO2002096888A1 (de) 2001-05-29 2002-12-05 Schering Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
WO2003022821A1 (fr) * 2001-09-06 2003-03-20 Taisho Pharmaceutical Co., Ltd. Derive d'heterocycle presentant une activite inhibitrice de l'enzyme de production du 20-hete
DK1438053T3 (da) * 2001-10-17 2008-12-08 Boehringer Ingelheim Pharma Pyrimidinderivater, lægemiddel indeholdende disse forbindelser, deres anvendelse og fremgangsmåder til deres fremstilling
DE10201240A1 (de) 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
FR2837201A1 (fr) 2002-03-18 2003-09-19 Servier Lab Nouveaux composes derives de la quinazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2479744A1 (en) * 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
AU2003225305A1 (en) * 2002-05-08 2003-11-11 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
EP1388535A1 (de) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylierte Arylcycloalkylamine und ihre Anwendung als Arzneimittelwirkstoff
EP1388341A1 (de) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Substituierte Acylamino heteroaromatische Verbindungen und ihre Verwendung als Arztneimittel
EP1388342A1 (de) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylierte, Heteroaryl-kondensierte Cycloalkenylamine und deren Verwendung als Arzneimittel
US7186735B2 (en) 2002-08-07 2007-03-06 Sanofi-Aventis Deutschland Gmbh Acylated arylcycloalkylamines and their use as pharmaceuticals
PL379330A1 (pl) * 2002-12-20 2006-08-21 Pfizer Products Inc. Pochodne pirymidyny dla leczenia nienormalnego wzrostu komórek
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
EP1587510A4 (de) * 2003-01-31 2007-08-08 Univ Hong Kong Verfahren zur behandlung von ischämischemschlaganfall mit melatonin
JP2004262890A (ja) * 2003-03-04 2004-09-24 Taisho Pharmaceut Co Ltd ２０−ｈｅｔｅ産生阻害作用を有するアゾール誘導体
JP2004269469A (ja) * 2003-03-12 2004-09-30 Yamanouchi Pharmaceut Co Ltd ピリミジン誘導体又はその塩
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
EP1471066A1 (de) 2003-04-24 2004-10-27 Aventis Pharma Deutschland GmbH Triaza- und Tetraaza-anthrazendionderivate, ihre Herstellung und Verwendung als Pharmazeutika
US7538233B2 (en) * 2003-09-05 2009-05-26 Aventis Pharmaceuticals Inc. Coumarins as iNOS inhibitors
AU2004291082A1 (en) * 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
ES2287896T3 (es) * 2004-01-12 2007-12-16 Laboratoires Serono Sa Derivados de tiazol y uso de los mismos.
GB0402809D0 (en) 2004-02-09 2004-03-10 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
DOP2006000146A (es) 2006-12-31
EP1741709A1 (de) 2007-01-10
HK1122551A1 (en) 2009-05-22
AR054800A1 (es) 2007-07-18
NO20080523L (no) 2008-01-28
PE20070102A1 (es) 2007-03-02
RU2412181C2 (ru) 2011-02-20
SI1899321T1 (sl) 2012-04-30
PA8683901A1 (es) 2007-01-17
EP1899321B1 (de) 2011-12-28
CY1112869T1 (el) 2016-04-13
AU2006264049B2 (en) 2012-04-12
GT200600274A (es) 2007-02-05
MX2008000044A (es) 2008-03-19
CA2611953A1 (en) 2007-01-04
ES2378894T3 (es) 2012-04-18
JP5149794B2 (ja) 2013-02-20
WO2007000246A1 (en) 2007-01-04
MA29552B1 (fr) 2008-06-02
AU2006264049A1 (en) 2007-01-04
CN101208328A (zh) 2008-06-25
TWI378095B (en) 2012-12-01
IL188382A0 (en) 2008-04-13
BRPI0613717A2 (pt) 2011-02-08
DK1899321T3 (da) 2012-04-16
NZ565041A (en) 2011-03-31
JP2008543958A (ja) 2008-12-04
ATE539072T1 (de) 2012-01-15
US8518976B2 (en) 2013-08-27
PL1899321T3 (pl) 2012-05-31
CN101208328B (zh) 2012-02-29
US20080171739A1 (en) 2008-07-17
TW200738673A (en) 2007-10-16
RS52266B (en) 2012-10-31
KR20080027801A (ko) 2008-03-28
PT1899321E (pt) 2012-03-19
ZA200710002B (en) 2008-11-26
RU2008102966A (ru) 2009-08-10
UY29640A1 (es) 2007-01-31
EP1899321A1 (de) 2008-03-19

Similar Documents

Publication Publication Date Title
HRP20120167T1 (hr) Heteroarilom supstituirani amidi koji sadrže zasićenu spojnicu i njihova upotreba kao farmaceutska sredstva
ES2739526T3 (es) Agonistas de APJ de 4-hidroxi-3-(heteroaril)piridin-2-ona para su uso en el tratamiento de trastornos cardiovaculares
RU2018123779A (ru) Новые соединения
ES2674088T3 (es) Inhibidores de la calicreína plasmática
HRP20200379T1 (hr) Spojevi pirimidindiona protiv srčanih stanja
JP2007513915A5 (de)
ES2642766T3 (es) Compuestos heterocíclicos conocidos y nuevos como agentes para combatir plagas
JP2007519735A5 (de)
RU2008141761A (ru) ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ
JP2007512349A5 (de)
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
JP2019504009A5 (de)
JP2017532360A5 (de)
JP2009524670A5 (de)
RU2009125897A (ru) Ингибиторы фосфоинозитид-3-киназы и способы их применения
RU2008107264A (ru) Производные пиразина, полезные в качестве антагонистов аденозинового рецептора
HRP20201430T1 (hr) Spojevi 6-heterociklil-4-morfolin-4-ilpiridin-2-ona korisni za liječenje karcinoma i dijabetesa
RU2010137300A (ru) Модуляторы бета-амилоида
JP2012528166A5 (de)
AR044499A1 (es) Pirimidinas sustituidas con indano inhibidoras de la replicacion del hiv
BR112014015669B1 (pt) Compostos derivados de piridinona e pirimidinona, composição farmacêutica que compreende os ditos compostos e uso dos mesmos para o tratamento ou prevenção de uma doença tromboembólica
RU2017118165A (ru) Ингибиторы энхансера гомолога 2 zestes
RU2009114857A (ru) Гетероциклические органические соединения
CA2522435A1 (en) Inhibitors of akt activity
HRP20140115T1 (hr) Inhibitori poli(adp-riboza)polimeraza